Vanguard Global Advisers
FBIO icon

Vanguard Global Advisers’s Fortress Biotech FBIO Stock Holding History

Vanguard Global Advisers’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.5K Hold
12,578
– – ﹤0.01% 3151
2026
Q1 		$35.1K Buy
+12,578
New +$42.7K ﹤0.01% 3153

Other funds holding FBIO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Global Advisers's FBIO Position: Q2 2026 in Review

Vanguard Global Advisers held its Fortress Biotech (FBIO) position steady in Q2 2026 at 12,578 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

Vanguard Global Advisers first reported a position in FBIO in Q1 2026 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold FBIO as of Q2 2026.

  • Vanguard Global Advisers held 12,578 shares of Fortress Biotech worth $38.5K as of Q2 2026.
  • Vanguard Global Advisers left its Fortress Biotech share count unchanged in Q2 2026.
  • Fortress Biotech made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3151 holding.
  • Vanguard Global Advisers first reported a position in Fortress Biotech in Q1 2026 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.